FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5


A.



LEGEND TO FIGURE 5.

- chemical linker
- toxic moiety
- immunoglobulin domains comprising immunoglobulin variable regions
- amino-acid residues linker, integrated via peptide bonds
- disulfide bonds
- immunoglobulin domains

B.



I. IgG provided with a chemically linked toxic moiety and comprising a variable region specific for a peptide derived from an intracellular tumor-specific protein and presented at the tumor cell surface in the context of MHC.	**II.** Bi-specific IgG provided with a chemically linked toxic moiety and comprising two different variable regions specific for one or two peptides derived from one or two intracellular tumor-specific protein(s) and presented at the tumor cell surface in the context of MHC.	**III.** IgG provided with a toxic moiety linked through a peptide linker integrated via peptide bonds, and comprising a variable region specific for a peptide derived from an intracellular tumor-specific protein and presented at the tumor cell surface in the context of MHC.	**IV.** Bi-specific IgG provided with one heavy chain comprising a toxic moiety linked through a peptide linker integrated via peptide bonds, and comprising two different variable regions specific for one or two peptides derived from one or two intracellular tumor-specific protein(s) and presented at the tumor cell surface in the context of MHC.

FIGURE 6






FIGURE 7



HLA-A0201/YLEYRQVPG specific nanobody binding to CMT64 mouse cells expressing HLA-A0201 with covalently linked YLEYRQVPG MAGE-A epitope.
No binding to CMT64 cells expressing HLA0201 with the FLWGPRALV epitope was seen.



HLA-A0201/FLWGPRALV specific nanobody binding to CMT64 mouse cells expressing HLA-A0201 with covalently linked FLWGPRALV MAGE-A epitope.
No binding to CMT64 cells expressing HLA0201 with the YLEYRQVPG epitope was seen.